Roche's taspoglutide notches further Phase III diabetes successes
This article was originally published in Scrip
Roche's once-weekly GLP-1 analogue taspoglutide has demonstrated non-inferiority to Sanofi-Aventis's Lantus (insulin glargine), and superiority to placebo, when used as an add-on to metformin, top-line results of its fourth and fifth Phase III trials show. The drug has now succeeded in meeting its primary endpoint in five of its eight Phase III trials. The first filing of the drug, and results from two more pivotal trials, are expected by the end of 2010.